Showing results (41-50 of 53) with videos related to
Sort By:
Pageof 6
Therapeutic Advances in Respiratory Disease|March 30, 2024
Perceived burden of respiratory physiotherapy in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor combination: a 1-year observational studyChiara Blardone, Simone Gambazza, Alessandra Mariani, et al.ACS Infectious Diseases|March 18, 2025
Identification of a New FtsZ Inhibitor by Virtual Screening, Mechanistic Insights, and Structure-Activity Relationship AnalysesPietro Sciò, Viola Camilla Scoffone, Anastasia Parisi, et al.Respiratory Research|December 16, 2023
Treatable traits and challenges in the clinical management of non-tuberculous mycobacteria lung disease in people with cystic fibrosisAndrea Gramegna, Sofia Misuraca, Andrea Lombardi, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 13, 2017
Lack of efficacy of Lactobacillus GG in reducing pulmonary exacerbations and hospital admissions in children with cystic fibrosis: A randomised placebo controlled trialEugenia Bruzzese, Valeria Raia, Eliana Ruberto, et al.Pediatric Nephrology (Berlin, Germany)|August 24, 2014
Hemoconcentration: a major risk factor for neurological involvement in hemolytic uremic syndromeGianluigi Ardissino, Valeria Daccò, Sara Testa, et al.Pediatric Research|May 22, 2026
Real-life effectiveness and safety of lumacaftor/ivacaftor in preschool children with cystic fibrosis: data from an italian multicentre studySantiago Presti, Chiara Cimbalo, Alberto Terminiello, et al.Archives of Disease in Childhood|July 27, 2012
Puberty is associated with increased deterioration of renal function in patients with CKD: data from the ItalKid ProjectGianluigi Ardissino, Sara Testa, Valeria Daccò, et al.European Journal of Pediatrics|July 1, 2021
Multiple, random spot urine sampling for estimating urinary sodium excretionGianluigi Ardissino, Antonio Vergori, Cesare Vergori, et al.The Journal of Pediatrics|June 30, 2024
Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor/Tezacaftor/IvacaftorVito Terlizzi, Cristina Fevola, Santiago Presti, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 29, 2007
No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy--report from the ItalKid Project databaseGianluigi Ardissino, Sara Viganò, Sara Testa, et al.Pageof 6